Etiological treatment combined with antifibrotic therapy （dual therapy） for liver cirrhosis： Current status and future perspectives
- VernacularTitle:肝硬化病因治疗联合抗纤维化治疗（双抗治疗）的现状与展望
- Author:
Yifan HAN
1
;
Xiaoyuan XU
1
Author Information
- Publication Type:Journal Article
- Keywords: Hepatic Fibrosis; Liver Cirrhosis; Dual-anti Therapy
- From: Journal of Clinical Hepatology 2026;42(6):1241-1245
- CountryChina
- Language:Chinese
- Abstract: Liver cirrhosis is the end-stage of various chronic liver diseases， and hepatic fibrosis caused by persistent inflammation is the core mechanism of the development and progression of liver cirrhosis. With the evolution of disease spectrum and a deeper understanding of the reversal of hepatic fibrosis， dual antiviral-antifibrotic therapy initially applied in the treatment of hepatitis B cirrhosis has gradually evolved into a broad-sense dual therapy for liver cirrhosis， which integrates etiological treatment with antifibrotic and/or anti-inflammatory interventions. This article systematically reviews the conceptual evolution of dual therapy for liver cirrhosis and related research advances.
